Amyris trialing bio-based vaccine adjuvants to replace demand for deep-sea shark livers
In California, Amyris, Inc. is currently delivering samples to pharmaceutical companies of a sustainable and scalable alternative to shark-based vaccine adjuvants currently used in a number of vaccines, including those directed at influenza and COVID-19. Amyris expects commercialization and production of its alternative squalene for adjuvants in the fourth quarter. Adjuvants are added to vaccines […]









